Feasibility Evaluation of Emodin (Rhubarb Extract) as an Inhibitor of Pancreatic Cancer Cell Proliferation In Vitro

Abstract

Emodin is a commonly used traditional herbal treatment in China, including use for pancreatic malignancy. In this study, the potential for emodin to inhibit pancreatic cancer cell proliferation was examined using 4 human pancreatic adenocarcinoma cell lines: Mia Paca-2, BxPC-3, Panc-1, and L3.6pl. WST-1 proliferation, propidium iodide flow cytometry cell cycle analysis, and poly-ADP-ribose polymerase (PARP) Western blot analysis were performed. Forty-eight-hour treatment with 50 μM emodin inhibited proliferation in Mia Paca-2 cells by 42%, BxPc-3 by 38%, L3.6pl by 56%, and Panc-1 by 18% (all P < .01). In three-fourths of the cell lines, emodin treatment resulted in an increase (from 4.7% to 22%) in the cell population number in apoptosis when measured by flow cytometric analysis. Mia Paca-2 revealed a significant PARP cleavage product when compared with control. These feasibility experiments provide initial evidence that emodin exerts an antiproliferative effect, likely through apoptosis induction-related mechanism(s), that is reproducible in various human pancreatic cancer cell lines.

Emodin is a nutritional supplement with a potential for inhibitory effects on cancer. We have shown that emodin inhibits pancreatic cell proliferation in 4 distinct cell lines. The inhibition is likely through apoptosis induction shown with PARP cleavage and flow cytometry.

Get full access to this article

View all access options for this article.

References

Espat NJ, Brennan MF, Conlon KC. Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg.1999;188:649 -655.

Stathopoulos GP, Syrigos K, Polyzos A, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol. 2004;15:224 -229.

Carnero A. Targeting the cell cycle for cancer therapy. Br J Cancer. 2002;87:129 -133.

Jing X, Ueki N, Cheng J, Imanishi H, Hada T. Induction of apoptosis in hepatocellular carcinoma cell lines by Emodin. Jpn J Cancer Res. 2002;93:874 -882.

Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic path-way. Lancet Oncol.2003 ;4:721 -729.

Demirezer LO, Kuruuzum-Uz A, Bergere I, Schiewe HJ, Zeeck A. The structures of antioxidant and cytotoxic agents from natural source: anthraquinones and tannins from roots of Rumex patientia. Phytochemistry.2001 ;58:1213 -1217.

Wang HH, Chung JG. Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori. Curr Microbiol.1997 ;35:262 -266.

Chang CH, Lin CC, Yang JJ, Namba T, Hattori M. Anti-inflammatory effects of emodin from ventilago leiocarpa. Am J Chin Med.1996 ;24:139 -142.

Huang HC, Chang JH, Tung SF, Wu RT, Foegh ML, Chu SH. Immunosuppressive effect of emodin, a free radical generator. Eur J Pharmacol. 1992;211:359 -364.

10.

Sato M, Maulik G, Bagchi D, Das DK. Myocardial protection by protykin, a novel extract of trans-resveratrol and Emodin. Free Radic Res. 2000;32:135 -144.

11.

Goel RK, Das Gupta G, Ram SN, Pandey VB. Antiulcerogenic and anti-inflammatory effects of emodin, isolated from Rhamnus triquerta wall. Ind J Exp Biol.1991 ;29:230 -232.

12.

Srinivas G, Anto RJ, Srinivas P, Vidhyalakshmi S, Senan VP, Karunagaran D. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol. 2003;473:117 -125.

13.

Chen YC, Shen SC, Lee WR, et al. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol. 2002;64:1713 -1724.

14.

Jayasuriya H, Koonchanok NM, Geahlen RL, McLaughlin JL, Chang CJ. Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J Nat Prod. 1992;55:696 -698.

15.

Zhang L, Lau YK, Xi L, et al. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neuinduced cellular transformation and metastasis-associated properties. Oncogene.1998 ;16:2855 -2863.

16.

Zhang L, Chang CJ, Bacus SS, Hung MC. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res.1995 ;55:3890 -3896.

17.

Lee HZ. Protein kinase C involvement in aloe-emodin and emodin induced apoptosis in lung carcinoma cell. Br J Pharmacol.2001 ;134:1093 -1103.

18.

Lee HZ. Effects and mechanisms of emodin on cell death in human lung squamous cell carcinoma. Br J Pharmacol.2001 ;134:11 -20.

19.

Jayasuriya H, Koonchanok NM, Geahlen RL, McLaughlin JL, Chang CJ. Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J Nat Prod. 1992;55:696 -698.

20.

Yi J, Yang J, He R, et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res.2004 ;64:108 -116.

21.

Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res.1999 ;5:343 -353.

22.

Su YT, Chang HL, Shyue SK, Hsu SL. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol.2005 ;70:229 -241.

23.

Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res.1999 ;5:119 -127.

24.

Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg.2004 ;198:591 -599.